Monovalent Blood Brain Barrier Shuttle Modules for Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for delivering neurological disorder drugs across the blood-brain barrier (BBB) are limited by the impermeable nature of the BBB, resulting in low brain penetration and pharmacological efficacy.
Innovation Solution
A blood brain barrier shuttle module comprising a brain effector entity, a linker, and a monovalent binding entity that specifically binds to a blood brain barrier receptor, thereby facilitating the transport of therapeutic agents across the BBB.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If monoclonal antibodies or peptides are designed to bind to blood brain barrier receptors for receptor-mediated delivery, then brain uptake is enhanced, but miss-sorting within brain endothelial cells and accumulation in degrading organelles increases
Solution Approach 1:
The patent divides the binding entity into monovalent units (single binding sites) rather than using multivalent antibodies. This segmentation prevents cross-linking of receptors and reduces miss-sorting within brain endothelial cells, while still achieving effective brain uptake through receptor-mediated transcytosis
Solution Approach 2:
The patent applies local quality by creating heterovalent constructs where one end has monovalent binding specificity for BBB receptors (to ensure accurate targeting and transcytosis), while the other end contains the therapeutic payload (antibody or peptide). This localized functional differentiation optimizes both delivery efficiency and accuracy
2Object-affected harmful factors
If the blood brain barrier is made impermeable to protect the brain, then brain protection is improved, but drug delivery to the brain deteriorates
Solution Approach 1:
The patent uses monovalent binding entities as intermediaries that specifically bind to blood brain barrier receptors (such as transferrin receptors). These intermediaries facilitate the transport of therapeutic antibodies or peptides across the BBB by hijacking the natural transcytosis pathway, thereby enabling drug delivery without compromising the barrier's protective function
Solution Approach 2:
The patent exploits the universal transcytosis pathway used by endogenous ligands (like transferrin) and applies it to therapeutic molecules. By designing monovalent binding entities that mimic natural ligands, the system achieves multi-functionality: the same receptor-mediated pathway serves both physiological nutrient transport and therapeutic drug delivery
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The shuttle module effectively enhances the brain uptake of neurological disorder drugs while minimizing miss-sorting and degradation within brain endothelial cells, thereby improving pharmacological efficacy.
Implementation Method 1
a monovalent binding entity which binds to a blood brain barrier receptor (BBBR)
Data Source
AI summary
Herein is reported a blood brain barrier shuttle module comprising a brain effector entity, a linker and one monovalent binding entity which binds to a blood brain barrier receptor, wherein the linker couples the effector entity to the monovalent binding entity which binds to the blood brain barrier receptor wherein the monovalent binding entity does not comprise the variable domains of the anti-transferrin receptor antibody 8D3 (SEQ ID NO: 01 and SEQ ID NO: 02) or of the variant anti-transferrin receptor antibody 8D3v (SEQ ID NO: 01 and SEQ ID NO: 03).